Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Santen Pharmaceutical Co., Ltd. has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct examiners and 2 distinct art units. This indicates that while the portfolio is small, it is spread across more than one administrative group at the patent office. The involvement of multiple art units suggests that the company's pharmaceutical innovations may touch upon different specialized sub-fields.
The busiest examiner for the company is SOROUSH, LAYLA, who handles 1 pending office action. Since there are 3 pending office actions and 3 distinct examiners, each examiner is responsible for exactly one matter. This one-to-one ratio between actions and examiners means that practitioners must coordinate with three different individuals across 2 distinct art units. This lack of examiner overlap prevents the consolidation of prosecution efforts under a single official. Practitioners should be prepared to address the specific nuances of each examiner's style, even though the total volume of 3 pending office actions is relatively low.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Double-patenting only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269474 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF | STEVENS, MARK V | 28d |
| 18851269 | STERILIZATION METHOD OF PHARMACEUTICAL PREPARATION AND PACKAGING | SOROUSH, LAYLA | — |
| 18625513 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18851269 | STERILIZATION METHOD OF PHARMACEUTICAL PREPARATION AND PACKAGING | SOROUSH, LAYLA | — | §103 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18625513 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | RODRIGUEZ, RAYNA B | 1628 | DP | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18269474 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF | STEVENS, MARK V | 1613 | §103 | Non-Final OA | 28d | Pending | Jun 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial